



## *MolMed and Collectis signed a development and manufacturing agreement in the field of allogeneic CAR T-cells*

Milan (Italy) & New York (N.Y.), July 27, 2017 – MolMed S.p.A. (“MolMed”) and Collectis (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced having entered into a development and manufacturing agreement in the field of allogeneic CAR T-cell products.

In recent years, the “chimeric antigen receptors” (CAR) have become one of the most promising innovative therapeutic strategies in oncology. CARs are proteins that allow T lymphocytes to recognize a specific antigen on targeted tumour cells. This approach is expected by the scientific community to bring revolutionary treatments to patients affected by aggressive tumours resisting traditional therapies. Collectis develops UCARTs (Universal Chimeric Antigen Receptor T-cells) that are “off-the-shelf” allogeneic CARs. Their production can be industrialized and standardized with consistent pharmaceutical release criteria. Collectis’ UCARTs are the first “off-the-shelf” allogeneic CAR T-cell product candidates in the clinic, and are meant to be readily available for large patient populations.

Under the terms of this agreement, Collectis entrusts MolMed to develop and manufacture viral vectors and Collectis’ genetically engineered allogeneic CAR T-cells. .

Riccardo Palmisano, CEO commented: *“We are very delighted to announce this collaboration with Collectis: it once again confirms MolMed’s well recognised excellence in development and manufacturing of gene therapy products for third parties, thus further reinforcing MolMed’s second pillar for future growth. This agreement seals a strategic collaboration with such a cutting edge innovative company”.*

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

---

### FROM GENES TO THERAPY

#### **MOLMED S.p.A.**

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325  
info@molmed.com - [www.molmed.com](http://www.molmed.com)

Share capital €20,312,682.30 i.v- Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



PRESS RELEASE

### *About MolMed*

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

### *About Cellectis*

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells. Using its life-science-focused, pioneering genome engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: [www.cellectis.com](http://www.cellectis.com)

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.



PRESS RELEASE

**For further information:**

**MolMed S.p.A.:**

**Laura Villa**

**Investor Relations & Communication Director**

MolMed S.p.A.

phone: +39 02 21277.205

fax: +39 02 21277.325

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

**Press agent**

**Federico Ferrari**

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: [ferrari@secrp.it](mailto:ferrari@secrp.it)

**Collectis IR contact:**

**Simon Harnest,**

**VP of Corporate Strategy and Finance**

Collectis

phone: +1 646-385-9008

email: [simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)

**Collectis Media contacts:**

**Jennifer Moore,**

Collectis

**VP of Communications**

Phone: +1 917-580-1088

Email: [media@collectis.com](mailto:media@collectis.com)

**Caitlin Kasunich,**

KCSA Strategic Communications,

phone: +1 212-896-1241

email: [ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)

**DISCLAIMER**

*This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.*

**DISCLAIMER COLLECTIS**

*This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in filings Collectis makes with the Security Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.*

**FROM GENES TO THERAPY**